First patient enrolled in second phase III trial of Urocidin
Endo Pharmaceuticals and Bioniche Life Sciences have enrolled the first patient in the second phase III clinical trial of Urocidin.
The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer. About 450 patients are enrolled for this new trial at 120 clinical sites worldwide.
Urocidin is a mycobacterial cell wall-DNA complex (MCC) that has a dual mode of action: immune stimulation and direct anticancer activity. It treats bladder cancer by trans-urethral catheter injections directly into the bladder. MCC then interacts with the cells of the immune system and bladder cancer cells.